Could a new drug free PAH patients from daily pump therapy?

NCT ID NCT07700303

Not yet recruiting Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests whether people with pulmonary arterial hypertension (PAH) who are doing well on the drug sotatercept can safely stop their background prostacyclin therapy. Prostacyclin drugs can cause side effects and are hard to manage. The trial compares patients who slowly stop prostacyclin therapy with those who continue it, to see if stopping is safe and does not worsen their condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sotatercept
What this could lead to: If successful, this could allow some PAH patients to stop troublesome prostacyclin therapies, reducing side effects and simplifying treatment.
What could go wrong: This is a small, early-stage study, and stopping background therapy may worsen PAH in some patients. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Alberta Hospital

Edmonton, Alberta, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.